Lirimilast

Drug Profile

Lirimilast

Alternative Names: BAY 198004

Latest Information Update: 02 Sep 2005

Price : $50

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 02 Sep 2005 No development reported - Phase-II for Chronic obstructive pulmonary disease in Europe (PO)
  • 02 Sep 2005 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA (PO)
  • 12 Jul 2002 A clinical study has been added to the Respiratory Tract Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top